Pharma USA 2023: IRA Impact on Patients

Pharm Exec’s 20th Annual Pipeline Report examines the emerging drug development trends and surging investments in five expanding therapeutic areas.

Fran Gregory, VP of Emerging Therapies, Cardinal Health discusses her career, how both CAR-T therapies and personalization have been gaining momentum and what kind of progress we expect to see from them, some of the biggest hurdles facing their section of the industry, the importance of patient advocacy and so much more.

A look at the M&A and stock market pictures for full-year 2024—and the potential strategic implications for pharma and biotech ahead.

Our milestone 100th episode includes Lisa Henderson, group editorial director; Julian Upton, European and online editor; Fran Pollaro, senior editor; and Andy Studna, associate editor, discussing industry trends in areas such as Chinese biotech, corporate branding, psychedelic medicines, and market access barriers.

A surge in biotech startup out-licensing deals from the country are paving the way for increased IPO and M&A activities.

Panel participants share an optimistic outlook for integrating new innovations, tacking community-level challenges, and more.